Combination Drug articles & resources on Made-in-China.com

Rollprint Packaging Develops New Peelable Exponent for Single Dose Applications

Sep 11, 2015

Flexible packaging material supplier Rollprint Packaging Products has added a new easy-to-open package Peelable Exponent to its Barex replacement product range. The new peelable Barex replacement structure has been developed for ...

Tags: Flexible packaging, Peelable Exponent, Rollprint

The FDA Will Address OTC Acetaminophen Products in Another Regulatory Action

Jan 17, 2014

WASHINGTON, Jan. 15 (UPI) -- The U.S. Food and Drug Administration recommends health professionals discontinue prescribing combination drug products containing acetaminophen. The FDA recommends healthcare professionals discontinue ...

Tags: FDA, OTC, acetaminophen, acetaminophen-containing product

FDA Has Approved GlaxoSmithKline's Use of Mekinist in Combination with Tafinlar

Jan 13, 2014

The US Food and Drug Administration (FDA) has approved GlaxoSmithKline's (GSK) use of Mekinist (trametinib) in combination with Tafinlar (dabrafenib) for the treatment of patients with unresectable melanoma or metastatic melanoma with BRAF ...

Tags: FDA, Combination Drug

FDA Approved Roche's Drug Gazyva in Combination with Chlorambucil Chemotherapy

Nov 5, 2013

The US Food and Drug Administration (FDA) has approved Roche's new drug Gazyva (obinutuzumab) in combination with chlorambucil chemotherapy for treatment of patients with chronic lymphocytic leukemia (CLL) who have not previously been ...

Tags: Combination Vaccine, Medicine

GSK Has Submitted a NDA to The US FDA for The Once Daily ICS Treatment

Oct 28, 2013

GlaxoSmithKline (GSK) has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for the once daily inhaled corticosteroid (ICS) treatment, fluticasone furoate (FF), administered using the ELLIPTA dry powder ...

Tags: Asthma Treatment, Medicine

GSK and Danish Biotechnology Firm Genmab Have Filed a Supplemental Agreement

Oct 22, 2013

GlaxoSmithKline (GSK) and Danish biotechnology firm Genmab have filed a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) for the use of its leukaemia drug Arzerra (ofatumumab) in combination ...

Tags: GlaxoSmithKline, CLL Patients

Basilea Pharmaceutica Has Submitted a Marketing Authorization Application

Dec 5, 2012

Basilea Pharmaceutica has submitted a marketing authorization application (MAA) under the European decentralized procedure for its novel investigational antibiotic, ceftobiprole, to treat pneumonia in hospitals. The submission of the ...

Tags: MRSA, ceftobiprole, novel investigational antibiotic